What is Qualtex?
Founded in 2007 and headquartered in San Antonio, Texas, Qualtex Laboratories operates as a specialized subsidiary of BioBridge Global. The company provides a comprehensive suite of diagnostic services, including infectious disease testing, source plasma donor screening, and immunohematology reference laboratory support. As a key player in the life sciences industry, Qualtex serves a diverse clientele ranging from blood centers to clinical research organizations. Its market position is defined by its ability to execute high-volume, FDA-regulated assays while maintaining the precision required for HCT/P donor screening and complex potency assays. The firm's dual-facility model allows for robust redundancy and scalability in its testing operations.
How much funding has Qualtex raised?
Qualtex has raised a total of $850K across 2 funding rounds:
Debt
$350K
Debt
$500K
Debt (2020): $350K with participation from PPP
Debt (2021): $500K led by PPP
Key Investors in Qualtex
PPP
Public-Private Partnership
What's next for Qualtex?
With the recent influx of capital, Qualtex is well-positioned to accelerate its research and development initiatives, particularly in the realm of non-FDA licensed assays and advanced clinical trial support. The strategic focus will likely shift toward enhancing throughput capabilities and integrating next-generation diagnostic technologies to meet the evolving demands of the biopharmaceutical and healthcare sectors. As the company navigates the complexities of the post-pandemic regulatory landscape, this financing provides the necessary liquidity to maintain its competitive edge in clinical research services and biological product safety, ensuring long-term stability for its donor and patient stakeholders.
See full Qualtex company page
